Text Size

Prevalence of Gastroesophageal Reflux Disease (GERD) in Patients With Upper Gastrointestinal Track (GIT) Symptoms in Thailand (GerdQ)

This study has been completed.
Sponsor:
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00999063
First received: October 20, 2009
Last updated: March 30, 2011
Last verified: March 2011
History of Changes

October 20, 2009
March 30, 2011
December 2009
February 2011   (final data collection date for primary outcome measure)
Prevalence of gastroesophageal reflux disease (GERD) in patients presented with upper gastrointestinal tract symptoms [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00999063 on ClinicalTrials.gov Archive Site
Response to various treatments for patients who have been diagnosed of GERD [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Prevalence of Gastroesophageal Reflux Disease (GERD) in Patients With Upper Gastrointestinal Track (GIT) Symptoms in Thailand
Prevalence of GERD in Patients With upperGITsymptoms in Thailand

This is a prospective , epidemiological, multi-centre, phase IV study, approximately 5,000 patients who suffer with upper gastrointestinal tract symptoms. Each patient will be assessed for GERD with GerdQ Thai Version.
Not Provided
Observational
Time Perspective: Prospective
Not Provided
Not Provided
Probability Sample

Primary care clinic
Upper GIT Symptoms
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
4108
February 2011
February 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Provision of informed consent prior to any study specific procedures
  • Female or male aged at least 18 years
  • Patient must be having symptoms suggestive of upper gastrointestinal tract symptoms such as heart burn/ regurgitation

Exclusion Criteria:

  • Involvement in the planning and /or conduct of the study (applies to both AstraZeneca staff and /or staff at study site
  • Participation in a clinical study(excluding non-interventional study or registry) during the last 3 months
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Thailand
 
NCT00999063
NIS-GTH-NEX-2009/1
No
Sompob Paibulsirijit, MD, Vice President Medical& Regulatory Affairs department, AstraZeneca
AstraZeneca
Not Provided
Principal Investigator: Somchai Leelasukolvong, Dr. Siriraj Hospital
AstraZeneca
March 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP